EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies

Adrian Gervais, Astrid Marchal, Alexis Maillard, Tom Le Voyer, Jérémie Rosain, Quentin Philippot, Lucy Bizien, Jessica Peel, Axel Cederholm iD, Mélanie Migaud, Sylvie Pons, Kahina Saker und 48 weitere

Proceedings of the National Academy of Sciences · 04.08.2026 · 123 (31)

DOI: 10.1073/pnas.2518581123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 31.07.2026. Verfasst von Adrian Gervais und 59 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris 75015, France. Hauptthemen laut MEDLINE: Autoantibodies, Myasthenia Gravis, Interferon Type I, Hypoxia. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche (ANR), Rockefeller University (The Rockefeller Institute), Stavros Niarchos Foundation (SNF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with myasthenia gravis (MG) may produce autoantibodies neutralizing type I interferons (AAN-I-IFN), which underlie severe viral diseases, including critical COVID-19 pneumonia, in patients without MG. We studied an international cohort of 85 unvaccinated SARS-CoV-2-infected MG patients not given antiviral treatment. Hypoxemic pneumonia occurred in 48 of these patients, including 22 (45.8%) with AAN-I-IFN, which neutralized both IFN-α2 and IFN-ω in 14 (29.2%) patients. Six (16.2%) of the remaining 37 patients had AAN-I-IFN, neutralizing both IFN-α2 and IFN-ω in three patients. The risk of hypoxemic pneumonia was greater in MG patients with AAN-I-IFN neutralizing 10 ng/mL of both IFN-α2 and IFN-ω (odds ratio and 95% confidence interval (OR [95% CI]): 12.7 [2.1 to 78.9], P = 0.0010) or IFN-α2 at any dose (OR [95% CI]: 4.7 [1.5 to 15.0], P = 0.0054) than in those without such autoantibodies. The risk of producing AAN-I-IFN was much higher in MG patients than in the general population (OR [95% CI]: 28.9 [10.8 to 77.7], P = 4.9 × 10 −27 ). Thymoma was found in 14 patients and increased the risk of AAN-I-IFN (64% versus 27%, (OR [95% CI]: 5.6 [1.6 to 19.4], P = 0.0050) and hypoxemic pneumonia (9.2 [1.9 to 44.2]; P = 0.0019). Thymoma is, thus, associated with a higher risk of producing AAN-I-IFN, which are, in turn, associated with a higher risk of developing life-threatening COVID-19 pneumonia in patients with MG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesMyasthenia GravisInterferon Type IHypoxiaHumansFemaleMaleCOVID-19Middle AgedSARS-CoV-2AgedAdultInterferon-alphaPandemicsRisk Factors

Stichwörter der Autor:innen

COVID-19autoantibodiesinterferonsmyasthenia gravis

Substanzen

AutoantibodiesInterferon Type IInterferon-alpha

Autor:innen und Institutionen

  • Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris 75015, France.
  • Imagine Institute, Paris Cité University, Paris 75015, France.
  • Study Center for Primary Immunodeficiencies, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris, Paris 75015, France.
  • St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065.
  • Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala 75237, Sweden.
  • Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite 69495, France.

ORCID-Profile: Axel Cederholm, Vivien Béziat, Qiang Pan-Hammarström, Lennart Hammarström

Förderung

  • Agence Nationale de la Recherche (ANR)
  • Rockefeller University (The Rockefeller Institute)
  • Stavros Niarchos Foundation (SNF)
  • Fondation du Souffle (FdS)
  • Imagine Institute, France
  • Fondation pour la Recherche Médicale (FRM)
  • Battersea and Bowery Advisory Group
  • Fisher Center for Alzheimer's Research Foundation (Fisher Center)

Zitieren

APA

Gervais, A., Marchal, A., Maillard, A., Le Voyer, T., Rosain, J., Philippot, Q., Bizien, L., Peel, J., Cederholm, A., Migaud, M., Pons, S., Saker, K., Laforet, P., Aubart, M., Gitiaux, C., Biggs, C. M., Lopez, R. L., Souvannanorath, S., Tard, C., …, & Abel, L. (2026). High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies. Proceedings of the National Academy of Sciences, 123(31). https://doi.org/10.1073/pnas.2518581123

Vancouver

Gervais A, Marchal A, Maillard A, Le Voyer T, Rosain J, Philippot Q, et al. High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies. Proceedings of the National Academy of Sciences. 2026;123(31). doi:10.1073/pnas.2518581123

BibTeX
@article{Gervais2026,
  author = {Gervais, Adrian and Marchal, Astrid and Maillard, Alexis and Le Voyer, Tom and Rosain, Jérémie and Philippot, Quentin and Bizien, Lucy and Peel, Jessica and Cederholm, Axel and Migaud, Mélanie and Pons, Sylvie and Saker, Kahina and Laforet, Pascal and Aubart, Mélodie and Gitiaux, Cyril and Biggs, Catherine M and Lopez, Rafael Leon and Souvannanorath, Sarah and Tard, Céline and Pakleza, Aleksandra Nadaj and Grapperon, Aude-Marie and Heming, Nicholas and Annane, Djillali and Verschueren, Annie and Attarian, Shahram and Bigaut, Kévin and Hankiewicz, Karolina and Kouton, Ludivine and Villar-Quiles, Rocio-Nur and Cauquil, Cécile and Fleury, Marie-Céline and Rocher, Emilie and Nicolas, Guillaume and de Paula Estephan, Eduardo and da Penha Ananias Morita, Maria and Zanoteli, Edmar and Saied, Zakaria and Rachdi, Amine and Rim, Amouri and Belal, Samir and Ben Sassi, Samia and Hübers, Annemarie and Faure, Emmanuel and Desguerre, Isabelle and Basse, Clémence and Girard, Nicolas and Béziat, Vivien and Pan-Hammarström, Qiang and Hammarström, Lennart and Bodansky, Aaron and Parent, Audrey V and Anderson, Mark S and DeRisi, Joseph L and Demeret, Sophie and Truffault, Frédérique and Fort, Romain and Ader, Florence and Wallet, Florent and Trouillet-Assant, Sophie and Abel, Laurent},
  title = {High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {31},
  doi = {10.1073/pnas.2518581123}
}
Kostenlos starten →